Tolerability of non-ergot oral and transdermal dopamine agonists in younger and older Parkinson’s disease patients: an European multicentre survey

In older patients with Parkinson’s disease (PD), the use of dopamine agonists (DA) has been limited due to uncertainties related to their tolerability in spite of potential gains with the advent of longer acting or transdermal therapies. Comparative real-life data addressing the tolerability of DA t...

Descripción completa

Detalles Bibliográficos
Autores principales: Rizos, A., Sauerbier, A., Falup-Pecurariu, C., Odin, P., Antonini, A., Martinez-Martin, P., Kessel, B., Henriksen, T., Silverdale, M., Durner, G., Ray Chaudhuri, K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Vienna 2020
Materias:
Neurology and Preclinical Neurological Studies - Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7248021/
https://www.ncbi.nlm.nih.gov/pubmed/32372166
http://dx.doi.org/10.1007/s00702-020-02168-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7248021/
https://www.ncbi.nlm.nih.gov/pubmed/32372166
http://dx.doi.org/10.1007/s00702-020-02168-0

Ejemplares similares